Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ikke-farmakologiske behandlinger for parasomnier (Hypnosomnia)

5. november 2026 opdateret af: Chantal Berna Renella

Evaluering af effektiviteten af ​​ikke-farmakologiske behandlinger for parasomnier: et randomiseret kontrolleret forsøg

The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis (N=60).

Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis.

Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).

  • An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography (EEG). Estimated duration: 2h.
  • A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second EEG will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs).

This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.

For the validation of the EEG methodology, healthy volunteers (N=50) will complete a unique visit resembling the initial study visit of patients.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

110

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Canton of Vaud
      • Lausanne, Canton of Vaud, Schweiz, 1005
        • Centre hospitalier universitaire vaudois (CHUV)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Patients with NREM parasomnia (N=60):

Inclusion Criteria:

  • Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders
  • Willling and able to give informed consent
  • Reporting at least one parasomniac episode per month
  • Reporting at least one parasomniac episode the month prior

Exclusion Criteria:

  • Refusal to use the home video recording device
  • Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
  • A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
  • A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) >= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
  • A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)

Healthy volunteers (N=50):

Inclusion Criteria:

- Adult (≥ 18 yo) willing and able to give informed consent.

Exclusion criteria:

  • Presence of NREM parasomnias diagnosis, or any other concomitant sleep disorder;
  • Current intake of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines);
  • A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia);
  • A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder);
  • Current history of psychiatric or neurological disorders (e.g., migraines).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Medical hypnosis (HYP) (N=30)

3 medical hypnosis interventions

Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)

Aktiv komparator: Standard Of Care (SOC) (N=30)

3 standard of care quality and sleep safety interventions

Sleep hygiene and safety education session

Ingen indgriben: Healthy volunteers (N=50)

Unique EEG visit resembling the initial study visit of patients with NREM parasomnias

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
Tidsramme: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment

Parasomniac episodes scored on infrared home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Duration of parasomniac episodes
Tidsramme: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment

Using home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
Rate of confusional arousals, sleepwalking and sleep terrors episodes
Tidsramme: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment

Categorization of parasomniac episodes' complexity (confusional arousals, sleepwalking, sleep terrors) using home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
Incidence of emotions related to parasomniac episodes
Tidsramme: Through study duration, an average of 9 weeks

Emotional impact of parasomniac episodes using questionnaires (e.g., What emotions did you feel during these episodes?; Do you have negative emotions related to your parasomnias?)

Through study duration, an average of 9 weeks
Quality of life score
Tidsramme: At Day 0, Week 11 and Week 18

Using a standardized questionnaire: World Health Organization Quality Of Life-BREF (WHOQOL-BREF). Score ranging from 0 to 100, higher score denoting greater perceived quality of life.

At Day 0, Week 11 and Week 18
Anxiety and depression scores
Tidsramme: At Day 0 and Week 11

Using a standardized questionnaire: Hospital Anxiety and Depression Scale (HADS). Subscale score ranging from 3 to 21, score >8 denotes anxiety or depression.

At Day 0 and Week 11
Traumatic events score
Tidsramme: At Day 0

Using a standardized questionnaire: Life Event Checklist for DSM-5 (LEC-5). It does not yield a total score or a composite score.

At Day 0
Fatigue score
Tidsramme: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Pichot's fatigue scale. Score ranging from 0 to 32, score >22 denotes excessive fatigue.

At Week 2, Week 11 and Week 18
Sleepiness score
Tidsramme: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Epworth Sleepiness Scale (ESS). Score ranging from 0 to 24, higher score denoting higher daytime sleepiness.

At Week 2, Week 11 and Week 18
Sleep quality score
Tidsramme: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Pittsburgh Sleep Quality Index (PSQI). Score ranging from 0 to 21, higher score denoting greater acute sleep disturbances.

At Week 2, Week 11 and Week 18
Severity of arousal disorders score
Tidsramme: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Paris Arousal Disorders Severity Scale (PADSS). Score ranging from 0 to 50, higher score denoting more severed disorders.

At Week 2, Week 11 and Week 18
Circadian typology score
Tidsramme: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Horne & Östberg questionnaire. Score ranging from 16 to 86, higher score denoting morningness and lower score eveningness.

At Week 2, Week 11 and Week 18
Changes in sleep architecture
Tidsramme: At Day 0 and Week 11

Using power spectral sleep EEG analysis including delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), sigma (12-16 Hz), and beta (18-30 Hz) frequency bands with Titanium, Embla®, NOX-A1®.

At Day 0 and Week 11
Sleep eye movements
Tidsramme: At Week 11 (optional)

Using power spectral sleep EOG analysis (left and right) with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep muscles activity
Tidsramme: At Week 11 (optional)

Using power spectral sleep EMG analysis (chin and anterior tibialis muscle) with Titanium, Embla®, NOX-A1®

At Week 11 (optional)
Sleep cardiac activity
Tidsramme: At Week 11 (optional)

Using power spectral sleep ECG analysis (P wave, QRS complex, QT interval, PR interval...) with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep oxygen saturation
Tidsramme: At Week 11 (optional)

Using sleep oxygen saturation measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep airflow
Tidsramme: At Week 11 (optional)

Using sleep airflow measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep respiratory efforts
Tidsramme: At Week 11 (optional)

Using abdominal and thoracic respiratory efforts measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Snoring
Tidsramme: At Week 11 (optional)

Using snoring measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Changes in imagery processes
Tidsramme: At Day 0 and Week 11 for patients.

Using patients' EEG measures (N=60) collected with a 124-channel waveguardTMoriginal EEG cap and during 3-minute pleasant imagery suggestion audio recordings.

At Day 0 and Week 11 for patients.
Validation of the EEG methodology for the imagery processes recordings
Tidsramme: At Day 0

Using healthy volunteers' EEG measures (N=50) collected with a 124-channel waveguardTMoriginal EEG and during 5-minute pleasant imagery suggestion audio recordings.

At Day 0

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Chantal Berna Renella, Prof, CHUV

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. august 2023

Primær færdiggørelse (Faktiske)

19. februar 2026

Studieafslutning (Faktiske)

15. august 2026

Datoer for studieregistrering

Først indsendt

2. juni 2023

Først indsendt, der opfyldte QC-kriterier

11. juli 2023

Først opslået (Faktiske)

20. juli 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • CER-VD 2023-01007

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .